Scarica l'app Stockscreener
11.08
1.69%
-0.18
Precedente Chiudi:
$11.26
Aprire:
$11.08
Volume 24 ore:
65,902
Relative Volume:
0.08
Capitalizzazione di mercato:
$847.06M
Reddito:
$54.55M
Utile/perdita netta:
$-193.57M
Rapporto P/E:
-3.8339
EPS:
-2.89
Flusso di cassa netto:
$-181.86M
1 W Prestazione:
-3.91%
1M Prestazione:
-5.47%
6M Prestazione:
-43.84%
1 anno Prestazione:
-48.44%
Intervallo 1D:
$10.96
$11.32
Intervallo di 1 settimana:
$10.96
$12.33
Portata 52W:
$8.18
$29.56
Nurix Therapeutics Inc Stock (NRIX) Company Profile
Nome
Nurix Therapeutics Inc
Settore
Industria
Telefono
(415) 660-5320
Indirizzo
1700 OWENS STREET, SUITE 205, SAN FRANCISCO
Confronta NRIX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NRIX
Nurix Therapeutics Inc
|
11.08 | 908.22M | 54.55M | -193.57M | -181.86M | -2.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.37 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
550.00 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
395.42 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
667.14 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.49 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Nurix Therapeutics Inc Stock (NRIX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-17 | Iniziato | Leerink Partners | Market Perform |
| 2024-12-10 | Iniziato | BTIG Research | Buy |
| 2024-12-06 | Iniziato | BMO Capital Markets | Outperform |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-10-11 | Iniziato | Jefferies | Buy |
| 2024-09-06 | Ripresa | Robert W. Baird | Outperform |
| 2024-07-31 | Iniziato | Truist | Buy |
| 2023-06-26 | Ripresa | Oppenheimer | Outperform |
| 2023-03-09 | Iniziato | Barclays | Overweight |
| 2023-02-28 | Iniziato | Oppenheimer | Outperform |
| 2022-10-11 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-05-31 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-02-10 | Iniziato | Wells Fargo | Equal Weight |
| 2021-12-29 | Iniziato | H.C. Wainwright | Buy |
| 2021-10-14 | Iniziato | SVB Leerink | Outperform |
| 2021-06-04 | Ripresa | Robert W. Baird | Outperform |
| 2021-04-30 | Ripresa | Piper Sandler | Overweight |
| 2021-04-30 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-04-14 | Iniziato | Berenberg | Buy |
| 2020-11-19 | Iniziato | Robert W. Baird | Outperform |
| 2020-08-18 | Iniziato | JP Morgan | Overweight |
| 2020-08-18 | Iniziato | Needham | Buy |
| 2020-08-18 | Iniziato | Piper Sandler | Overweight |
| 2020-08-18 | Iniziato | Stifel | Buy |
Mostra tutto
Nurix Therapeutics Inc Borsa (NRIX) Ultime notizie
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Insider Gwenn Hansen Sells 4,308 Shares - MarketBeat
What are Nurix Therapeutics Inc. company’s key revenue driversPost Market Recommendation For 2025 - jammulinksnews.com
Oppenheimer Reiterates Outperform Rating for Nurix Therapeutics (NRIX) | NRIX Stock News - GuruFocus
Is it the right time to buy Nurix Therapeutics Inc. stockMarket Forecast Insights For 2025 - jammulinksnews.com
Oppenheimer Adjusts Price Target for Nurix Therapeutics (NRIX) - GuruFocus
Why is Nurix Therapeutics Inc. stock attracting strong analyst attentionPre Market Review For Consistent Profits - jammulinksnews.com
How many analysts rate Nurix Therapeutics Inc. as a “Buy”Swing Trade Report To Watch Now - jammulinksnews.com
ARK Investment Management LLC Has $18.90 Million Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Nurix Therapeutics’ ring sells $46k in stock to cover tax obligations - Investing.com India
Nurix therapeutics (NRIX) CSO Hansen sells $51k in stock By Investing.com - Investing.com Nigeria
Nurix Therapeutics CFO van Houte sells $51,695 in shares By Investing.com - Investing.com India
Nurix therapeutics (NRIX) CSO Hansen sells $51k in stock - Investing.com
Nurix Therapeutics CFO van Houte sells $51,695 in shares - Investing.com
Nikko Asset Management Americas Inc. Sells 33,252 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Will Nurix Therapeutics Inc. Hold Gains Into CloseMulti-Bagger Potential Stock Forecast Tools Released - metal.it
Nurix Therapeutics (NASDAQ:NRIX) Trading Up 4.9%Still a Buy? - MarketBeat
Does Nurix Therapeutics Inc. stock pay reliable dividendsAI Trading Suggestions With Accuracy Focus Released - metal.it
Y Intercept Hong Kong Ltd Invests $374,000 in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
New York State Common Retirement Fund Boosts Stock Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
NRIX Stock Price and Chart — NASDAQ:NRIX - TradingView
Nurix Therapeutics Inc. Stock Chart Analysis: Bullish or Bearish Pattern FormingTrade Insight With Community Collaboration Supported - metal.it
Does Nurix Therapeutics Inc. stock perform well during market downturnsFree Stock Selection - jammulinksnews.com
What makes Nurix Therapeutics Inc. stock price move sharplyGet insider insights into market trends - jammulinksnews.com
How does Nurix Therapeutics Inc. generate profit in a changing economyAccelerated investment success - jammulinksnews.com
Massachusetts Financial Services Co. MA Has $511,000 Stock Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
What drives Nurix Therapeutics Inc. stock priceTremendous financial leverage - PrintWeekIndia
Nurix Therapeutics Inc. Stock Analysis and ForecastPhenomenal returns - PrintWeekIndia
Non-Hodgkin’s Lymphoma Market Forecast to Surge with Growing Adoption of Targeted and Cell-Based Therapies | DelveInsight - GlobeNewswire Inc.
H.C. Wainwright Maintains Nurix Therapeutics(NRIX.US) With Buy Rating, Maintains Target Price $34 - 富途牛牛
Is Nurix Therapeutics Inc. a good long term investmentExceptional trading results - Autocar Professional
Hussman Strategic Advisors Inc. Takes Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Stock Price Down 5.4%What's Next? - MarketBeat
Janux Therapeutics Receives Buy Rating from Leerink Partners Amid Strategic Initiatives and Long-Term Growth Potential - AInvest
What analysts say about Nurix Therapeutics Inc. stockUnmatched profit potential - jammulinksnews.com
Q3 EPS Forecast for Nurix Therapeutics Raised by Analyst - MarketBeat
Janux Therapeutics (JANX) Soars 2.31% on R&D Day Announcement - AInvest
Nurix Therapeutics Inc Azioni (NRIX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Nurix Therapeutics Inc Azioni (NRIX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| van Houte Hans | Chief Financial Officer |
Jul 30 '25 |
Sale |
12.01 |
4,304 |
51,695 |
40,914 |
| Ring Christine | Chief Legal Officer |
Jul 30 '25 |
Option Exercise |
0.00 |
10,532 |
0 |
47,850 |
| Ring Christine | Chief Legal Officer |
Jul 30 '25 |
Sale |
12.01 |
3,841 |
46,134 |
44,009 |
| Hansen Gwenn | Chief Scientific Officer |
Jul 30 '25 |
Option Exercise |
0.00 |
11,815 |
0 |
73,331 |
| Hansen Gwenn | Chief Scientific Officer |
Jul 30 '25 |
Sale |
12.01 |
4,308 |
51,743 |
69,023 |
| van Houte Hans | Chief Financial Officer |
May 02 '25 |
Sale |
11.33 |
6,198 |
70,243 |
33,724 |
0.40%
0.23%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):